A planning committee of the National Academies of Sciences, Engineering, and Medicine will organize and conduct a 1.5-day public workshop that brings together experts and key stakeholders from academia, government, industry, and non-profit organizations to explore the use of psychedelics and entactogens - including LSD, psilocybin, and MDMA - as treatments for psychiatric disorders, such as major depressive disorder, anxiety disorder, post-traumatic stress disorder and substance use disorders.
Invited presentations and discussions will be designed to:

• Review the current state of knowledge regarding the mechanisms of action and pharmacokinetic/pharmacodynamic properties of these compounds, including considering the impact of polypharmacy;
• Discuss the current evidence on the clinical efficacy of psychedelics and entactogens to treat psychiatric conditions, including exploring the role of adjunctive psychotherapy, whether hallucinogenic and dissociative side effects are essential to treatment efficacy, and clarifying the importance of psychosocial contexts;
• Consider the role of biomarkers to target treatments, stratify patients, and predict safety profiles;
• Explore appropriate clinical trial design, the need for standardization of treatment regimens, the challenge of blinding and accounting for placebo effects, and regulatory considerations;
• Discuss the impacts of these compounds' legal status and scheduling classifications on research;
• Explore questions of biomedical ethics such as those regarding patient protections and consent, standards of clinical training and quality assurance, off-label use, equitable access to treatment options, and engagement with public interest and experimentation;
• Discuss open research questions, policy needs, and opportunities to move the field forward.

The planning committee will develop the agenda for the workshop, select and invite speakers and discussants, and moderate the discussions. A proceedings of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.